Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Hold consensus from five brokerages (1 sell, 2 hold, 2 buy) with an average 1‑year target of $8.67 and analyst targets ranging roughly from $5 to $12.
• DRTS opened at $6.86 with a market cap of about $581.9M, a 50‑/200‑day SMA of $7.20/$5.42, a one‑year range of $2.30–$8.60, and reported a quarterly EPS of -$0.14 (missed by $0.01) with FY EPS forecast around -0.45.
• Alpha Tau is developing targeted alpha‑radiation therapy, with its lead product Alpha DaRT in clinical studies for recurrent/metastatic head and neck cancers, skin cancers and other solid tumors.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.6667.

A number of analysts recently weighed in on DRTS shares. Citigroup upped their target price on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Piper Sandler reissued a "neutral" rating and issued a $5.00 target price on shares of Alpha Tau Medical in a report on Wednesday, March 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Zacks Research raised Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 17th. Finally, HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, March 10th.

Alpha Tau Medical Stock Performance

DRTS opened at $6.86 on Friday. The stock's 50 day simple moving average is $7.20 and its 200-day simple moving average is $5.42. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.08. The stock has a market cap of $581.87 million, a PE ratio of -12.94 and a beta of 1.02. Alpha Tau Medical has a 1 year low of $2.30 and a 1 year high of $8.60.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its earnings results on Monday, March 9th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Sell-side analysts forecast that Alpha Tau Medical will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of DRTS. Trifecta Capital Advisors LLC acquired a new position in Alpha Tau Medical in the fourth quarter worth $48,000. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the third quarter worth $62,000. Bank of America Corp DE lifted its position in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Alpha Tau Medical in the 3rd quarter valued at about $170,000. 2.65% of the stock is owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.